capivasertib (Truqap)
Jump to navigation
Jump to search
Indications
- combined with fulvestrant improves progression-free survival among women with ER/PR-positive, HER2-negative or low, locally advanced breast cancer
- FDA-approved for advanced breast cancer[2]
Adverse effects
- >= 20%
- nausea, vomiting, diarrhea, stomatitis, fatigue, dermatitis,
- hypoglyemia, lymphopenia, leukopenia, neutropenia, anemia, hypertriglyceridemia, increased serum creatinine
Mechanism of action
- AKT inhibitor
More general terms
References
- ↑ John A Capivasterib Meets Primary Endpoint in Phase 3 Breast Cancer Trial. Clinical Advances in Breast Cancer. Nov 14, 2022 https://www.mdalert.com/ms/cabreast/article/capivasterib-meets-primary-endpoint
- ↑ 2.0 2.1 Bankhead C First AKT Inhibitor Approved for Advanced Breast Cancer. Capivasertib plus fulvestrant doubled progression-free survival versus fulvestrant-placebo MedPage Today November 17, 2023 https://www.medpagetoday.com/hematologyoncology/breastcancer/107431